论文部分内容阅读
药物的氧化代谢是对许多药物的效能、作用持续时间以及毒性的决定因素。这一高度可变过程受遗传、环境以及生理因素所控制。1977年发现抗高血压药异喹胍的主要代谢途径(4-羟化代谢)受多态型控制。有6～10%的白种人由于不能清除异喹胍故称之为乏代谢者(PoorMetabolizer,PMs);反之,大多数民族称为泛代谢者(Extensive Metabolizer,EMs)。受试者的表型是通过口服异喹胍10mg,收集8小时尿样,测量其中异喹胍与4-羟异喹胍之比
Oxidative metabolism of drugs is a determinant of the potency, duration of action, and toxicity of many drugs. This highly variable process is controlled by genetic, environmental, and physiological factors. In 1977 it was found that the major metabolic pathway (4-hydroxylated metabolism) of the anti-hypertensive drug, is controlled by the polymorphism. Six to 10% of Caucasians are called Poor Metabolizers (PMs) because they can not remove the isoquinquine, whereas most people are called Extensive Metabolizers (EMs). The subject’s phenotype was determined by oral administration of 10 mg of isoquinoline and 8 hours of urine sample,